India Approves First Dengue Vaccine QDENGA: Eligibility, Dosage, Benefits and Availability Explained

India has approved QDENGA (TAK-003), the country's first dengue vaccine, marking a major milestone in the fight against one of the nation's most common mosquito-borne diseases.

The vaccine offers protection against all four dengue virus serotypes and, unlike some earlier dengue vaccines, does not require prior blood testing to determine whether a person has previously been infected with dengue.

Health experts believe the approval could significantly strengthen dengue prevention efforts, especially in regions that experience seasonal outbreaks during the monsoon.

What Is QDENGA?

QDENGA (TAK-003) is a vaccine developed to help protect against dengue fever caused by all four known dengue virus serotypes.

A key advantage of the vaccine is that people do not need to undergo a blood test before vaccination, making it easier to administer on a larger scale.

The approval marks the first time India has cleared a dengue vaccine for use in the country.

Who Can Receive the Dengue Vaccine?

According to current approval guidelines, QDENGA is indicated for individuals aged 4 to 60 years.

Eligible recipients include:

• Children aged 4 years and above
• Teenagers
• Adults up to 60 years of age
• Individuals living in dengue-prone regions

People considering vaccination should consult a healthcare professional to determine whether it is appropriate based on their medical history.

How Many Doses Are Required?

QDENGA is administered in two doses.

The recommended schedule is:

• First dose: On the chosen vaccination date
• Second dose: Three months after the first dose

Completing both doses is recommended to achieve optimal protection.

What Makes This Vaccine Different?

One of the biggest advantages of QDENGA is that previous dengue infection does not need to be confirmed before vaccination.

Earlier dengue vaccines in some countries required pre-vaccination testing because the effectiveness and safety profile differed depending on whether the recipient had previously been infected.

QDENGA removes this requirement, simplifying the vaccination process.

Does It Protect Against All Types of Dengue?

Yes.

Dengue is caused by four different virus serotypes, and infection with one type does not provide complete immunity against the others.

QDENGA has been developed to provide protection against all four dengue virus serotypes, helping reduce the risk of severe disease associated with subsequent infections.

Who Should Avoid the Vaccine?

Although the vaccine has received approval, it may not be suitable for everyone.

Individuals should seek medical advice before vaccination if they:

• Have experienced a severe allergic reaction to any component of the vaccine
• Are pregnant
• Are breastfeeding
• Have a severely weakened immune system
• Are taking medications that suppress immunity

Healthcare providers can advise whether vaccination is appropriate based on individual health conditions and the latest clinical recommendations.

When Will QDENGA Be Available?

Although regulatory approval has been granted, the vaccine is not expected to be available nationwide immediately.

Its rollout will depend on factors such as:

• Commercial launch timelines
• Distribution through hospitals and vaccination centres
• Recommendations from national health authorities
• Availability across states and cities

The vaccine is expected to become available in phases over the coming months.

Is Vaccination Enough to Prevent Dengue?

No.

Doctors emphasise that vaccination is an additional layer of protection, not a replacement for mosquito control measures.

People should continue to:

• Eliminate stagnant water around homes
• Use mosquito repellents
• Wear full-sleeved clothing
• Install window screens where possible
• Seek prompt medical care if symptoms such as high fever, severe headache, joint pain, nausea or bleeding develop

These preventive measures remain essential to reducing dengue transmission.

A Significant Step in India's Public Health Efforts

The approval of QDENGA represents an important advancement in India's fight against dengue.

By offering protection against all four dengue virus types without requiring prior blood testing, the vaccine has the potential to improve access to preventive care for millions of eligible individuals.

However, experts stress that vaccination should complement—not replace—public health measures such as mosquito control, community awareness and early diagnosis.

Key Highlights

• India has approved QDENGA (TAK-003) as its first dengue vaccine.
• The vaccine is approved for people aged 4 to 60 years.
• No blood test is required before vaccination.
• QDENGA is administered in two doses, three months apart.
• The vaccine provides protection against all four dengue virus serotypes.
• Nationwide availability is expected to begin in phases over the coming months.
• Mosquito control measures remain essential even after vaccination.

Frequently Asked Questions (FAQs)

What is QDENGA?

QDENGA (TAK-003) is India's first approved dengue vaccine, designed to provide protection against all four dengue virus serotypes.

Who can receive the vaccine?

The vaccine is approved for individuals aged 4 to 60 years, subject to medical advice where appropriate.

Is a blood test required before vaccination?

No. Unlike some earlier dengue vaccines, QDENGA does not require prior testing for previous dengue infection.

How many doses are needed?

The vaccine is given in two doses, with the second dose administered three months after the first.

Who should consult a doctor before getting vaccinated?

Pregnant women, breastfeeding mothers, individuals with weakened immune systems and those taking immunosuppressive medicines should seek medical advice before vaccination.

Will the vaccine be available immediately?

No. Although approved, QDENGA is expected to be introduced gradually through hospitals and vaccination centres over the coming months.